Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in California: - Kaiser Permanente Downey Medical Center — Downey, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in California: - Cedars-Sinai Medical Center — Los Angeles, California
- Kaiser Permanente - Panorama City — Panorama City, California
Phase 3 Recruiting Industry
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Sites in California: - City of Hope — Duarte, California
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in California: - Alta Bates Summit Medical Center ( Site 0004) — Berkeley, California
- Moores Cancer Center ( Site 0003) — La Jolla, California
- Care Access - South Pasadena ( Site 0070) — Pasadena, California
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in California: - MemorialCare Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital of Orange County Main Campus - Orange — Orange, California
- Benioff Children's Hospital - Mission Bay — San Francisco, California
Phase 3 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Sites in California: - University of California, Fresno — Clovis, California
- University of California, San Diego — La Jolla, California
- Cedars-Sinai Medical Center — Los Angeles, California
- University of California, Los Angeles — Los Angeles, California
- University of California, Irvine — Orange, California
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …
Sponsor: BeOne Medicines
NCT ID: NCT06943872
Sites in California: - Uci Health Laguna Hills — Laguna Hills, California
- Chao Family Comprehensive Cancer Center — Orange, California
- Stanford Cancer Institute — Palo Alto, California
- Scripps Prebys Cancer Center — San Diego, California
Phase 3 Recruiting Network
This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML). Xylitol is a naturally occurring sugar compound foun…
Sponsor: Children's Oncology Group
NCT ID: NCT07022678
Sites in California: - Valley Children's Hospital — Madera, California
- Kaiser Permanente-Oakland — Oakland, California
Phase 2, Phase 3 Recruiting Industry
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at es…
Sponsor: Taiho Oncology, Inc.
NCT ID: NCT04256317
Sites in California: - Keck School of Medicine of USC — Los Angeles, California
- UC Irvine Health - Chao Family Comprehensive Cancer Center — Orange, California
Phase 3 Recruiting Industry
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Sponsor: Priothera SAS
NCT ID: NCT05429632
Sites in California: - City of Hope Comprehensive Cancer Center - Duarte — Duarte, California
- University of California Los Angeles (UCLA) - David Geffen School of Medicine — Los Angeles, California
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in California: - Pacific Cancer Medical Center, Inc — Anaheim, California
- TOI Clinical Research — Cerritos, California
- Stanford School of Medicine-Cancer Clinical Trials Office — Palo Alto, California
- California Cancer Associates for Research and Excellence — San Marcos, California
Phase 3 Recruiting Industry
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06104566
Sites in California: - Ascentage Investigative Site — Anaheim, California
Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in California: - MemorialCare Health System - Long Beach Medical Center ( Site 5421) — Long Beach, California
Phase 3 Recruiting Industry
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, …
Sponsor: Grifols Therapeutics LLC
NCT ID: NCT05645107
Sites in California: - GC2202 Study Site 115 — Huntington Park, California
Phase 2, Phase 3 Recruiting Industry
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white blood cells t…
Sponsor: AbbVie
NCT ID: NCT07581002
Sites in California: - City of Hope National Medical Center /ID# 279568 — Duarte, California
Phase 2 Recruiting NIH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in California: - Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- Kaiser Permanente-Fresno — Fresno, California
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317649
Sites in California: - Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- Kaiser Permanente-Fresno — Fresno, California
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- PCR Oncology — Arroyo Grande, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Kaiser Permanente Downey Medical Center — Downey, California
- City of Hope Comprehensive Cancer Center — Duarte, California
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in California: - Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Cedars-Sinai Medical Center — Los Angeles, California
- UCSF Medical Center-Parnassus — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Sponsor: BeOne Medicines
NCT ID: NCT05006716
Sites in California: - University of California San Diego (Ucsd) Moores Cancer Center — La Jolla, California
- Stanford Medicine — Palo Alto, California
- UCLA Santa Monica Cancer Care — Santa Monica, California
Phase 2 Recruiting Academic/Other
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…
Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in California: - City of Hope — Duarte, California
- Children's Hospital Los Angeles — Los Angeles, California
- UCLA Mattel Children's Hospital — Los Angeles, California
- UCSF Benioff Children's Hospital Oakland — Oakland, California
- UCSF — San Francisco, California
Phase 2 Recruiting Academic/Other
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the firs…
Sponsor: Etan Orgel
NCT ID: NCT05082519
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital Orange County — Orange, California
- UCSF School of Medicine — San Francisco, California
Phase 1, Phase 2 Recruiting Academic/Other
This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid …
Sponsor: Beat AML, LLC
NCT ID: NCT03013998
Sites in California: - UCLA Ronald Reagan Medical Center — Los Angeles, California
- University of California, San Francisco — San Francisco, California
Phase 1, Phase 2 Recruiting Academic/Other
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-…
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05849662
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- University of California San Francisco — San Francisco, California